In question: The scientific value of preclinical safety pharmacology and toxicology studies with cell-based therapies

Molecular Therapy Methods and Clinical Development

Volumn 1, Issue , 2014, Pages 14026-

  Broichhausen, Christiane ^a   Riquelme, Paloma ^a   Ahrens, Norbert ^a   Wege, Anja K ^a   Koehl, Gudrun E ^a   Schlitt, Hans J ^a   Banas, Bernhard ^a   Fändrich, Fred ^b   Geissler, Edward K ^a   Hutchinson, James A ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84907027941     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2014.26     Document Type: Article

References (51)

1. Geissler, EK and Hutchinson, JA (2013). Cell therapy as a strategy to minimize maintenance immunosuppression in solid organ transplant recipients. Curr Opin Organ Transplant 18: 408-415.
2. Juvet, SC, Whatcott, AG, Bushell, AR and Wood, KJ (2014). Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning. Am J Transplant 14: 750-763.
3. Barbon, CM, Davies, JK, Voskertchian, A, Kelner, RH, Brennan, LL, Nadler, LM et al. (2014). Alloanergization of human T cells results in expansion of alloantigen-specific CD8(+) CD28(-) suppressor cells. Am J Transplant 14: 305-318.
4. Bacchetta, R, Lucarelli, B, Sartirana, C, Gregori, S, Lupo Stanghellini, MT, Miqueu, P et al. (2014). Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells. Front Immunol 5: 16.
5. Moreau, A, Varey, E, Bouchet-Delbos, L and Cuturi, MC (2012). Cell therapy using tolerogenic dendritic cells in transplantation. Transplant Res 1: 13.
6. Amodio, G and Gregori, S (2012). Human tolerogenic DC-10: perspectives for clinical applications. Transplant Res 1: 14.
7. Macedo, C, Turquist, H, Metes, D and Thomson, AW (2012). Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation. Transplant Res 1: 16.
8. Riquelme, P, Geissler, EK and Hutchinson, JA (2012). Alternative approaches to myeloid suppressor cell therapy in transplantation: comparing regulatory macrophages to tolerogenic DCs and MDSCs. Transplant Res 1: 17.
9. Broichhausen, C, Riquelme, P, Geissler, EK and Hutchinson, JA (2012). Regulatory macrophages as therapeutic targets and therapeutic agents in solid organ transplantation. Curr Opin Organ Transplant 17: 332-342.
10. Riquelme, P, Tomiuk, S, Kammler, A, Fändrich, F, Schlitt, HJ, Geissler, EK et al. (2013). IFN-γ-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. Mol Ther 21: 409-422.
11. Hutchinson, JA, Riquelme, P, Sawitzki, B, Tomiuk, S, Miqueu, P, Zuhayra, M et al. (2011). Cutting edge: immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol 187: 2072-2078.
12. Hutchinson, JA, Riquelme, P, Brem-Exner, BG, Schulze, M, Matthäi, M, Renders, L et al. (2008). Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int 21: 728-741.
13. Hutchinson, JA, Brem-Exner, BG, Riquelme, P, Roelen, D, Schulze, M, Ivens, K et al. (2008). A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int 21: 742-754.
14. Hutchinson, JA, Roelen, D, Riquelme, P, Brem-Exner, BG, Witzke, O, Philipp, T et al. (2008). Preoperative treatment of a presensitized kidney transplant recipient with donor-derived transplant acceptance-inducing cells. Transpl Int 21: 808-813.
15. Hutchinson, JA, Gövert, F, Riquelme, P, Bräsen, JH, Brem-Exner, BG, Matthäi, M et al. (2009). Administration of donor-derived transplant acceptance-inducing cells to the recipients of renal transplants from deceased donors is technically feasible. Clin Transplant 23: 140-145.
16. Hutchinson, JA, Riquelme, P and Geissler, EK (2012). Human regulatory macrophages as a cell-based medicinal product. Curr Opin Organ Transplant 17: 48-54.
17. Ferrer, IR, Hester, J, Bushell, A and Wood, KJ (2014). Induction of transplantation tolerance through regulatory cells: from mice to men. Immunol Rev 258: 102-116.
18. Hutchinson, JA, Ahrens, N, Riquelme, P, Walter, L, Gruber, M, Böger, CA et al. (2014). Clinical management of patients receiving cell-based immunoregulatory therapy. Transfusion (epub ahead of print).
19. Regulation (EC) 1394/2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation No. 726/2004. Official Journal of the European Union L 324/121.
20. Commission Directive 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products. Official Journal of the European Union L 424/3.
21. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Official Journal of the European Union L 311/67.
22. European Medicines Agency. Committee for Medicinal Product for Human Use (CHMP) Guideline on Human Cell-based Medicinal Product. Doc. Ref. EMEA/CHMP/410869/2006.
23. Salmikangas, P, Flory, E, Reinhardt, J, Hinz, T and Maciulaitis, R (2010). Regulatory requirements for clinical trial and marketing authorisation application for cell-based medicinal products. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 53: 24-29.
24. Pugsley, MK, Authier, S and Curtis, MJ (2008). Principles of safety pharmacology. Br J Pharmacol 154: 1382-1399.
25. Pugsley, MK, Gallacher, DJ, Towart, R, Authier, S and Curtis, MJ (2008). Methods in safety pharmacology in focus. J Pharmacol Toxicol Method 58: 69-71.
26. European Medicines Agency. ICH Topic S 7 A. Safety Pharmacology Studies for Human Pharmaceuticals. Note for Guidance on Safety Pharmacology Studies for Human Use. CPMP/ICH/539/00.
27. Hutchinson, JA, Riquelme, P, Brown, D P, Sawitzki, B, Rehli, M, Tomiuk, S et al. (2010). Evidence that treatment with DHRS9+ regulatory macrophages induced by FcγRIII ligation and IFN-γ stimulation promotes renal allograft tolerance in patients. Transplantation 90: 184.
28. Irwin, S (1968). Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 13: 222-257.
29. Pruss, A and Garritsen, H (2013). Advanced therapy medicinal products-a multiple challenge. Transfus Med Hemother 40: 384-385.
30. Smith, MD, Brune, JC, Wildemann, B and Pruss, A (2013). Whither advanced therapy medicinal products? Transfus Med Hemother 40: 449-452.
31. Schneider, CK, Salmikangas, P, Jilma, B, Flamion, B, Todorova, LR, Paphitou, A et al. (2010). Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov 9: 195-201.
32. Warnecke, G, Hutchinson, JA, Riquelme, P, Kruse, B, Thissen, S, Avsar, M et al. (2009). Postoperative intravenous infusion of donor-derived transplant acceptance-inducing cells as an adjunct immunosuppressive therapy in a porcine pulmonary allograft model. Transpl Int 22: 332-341.
33. Bazin, R, Aubin, E, Boyer, L, St-Amour, I, Roberge, C and Lemieux, R (2002). Functional in vivo characterization of human monoclonal anti-D in NOD-scid mice. Blood 99: 1267-1272.
34. Ishihara, C, Tsuji, M, Hagiwara, K, Hioki, K, Arikawa, J and Azuma, I (1994). Transfusion with xenogeneic erythrocytes into SCID mice and their clearance from the circulation. J Vet Med Sci 56: 1149-1154.
35. Morgan, RA, Chinnasamy, N, Abate-Daga, D, Gros, A, Robbins, PF, Zheng, Z et al. (2013). Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36: 133-151.
36. Erdö, F, Bührle, C, Blunk, J, Hoehn, M, Xia, Y, Fleischmann, B et al. (2003). Host-dependent tumorigenesis of embryonic stem cell transplantation in experimental stroke. J Cereb Blood Flow Metab 23: 780-785.
37. Amariglio, N, Hirshberg, A, Scheithauer, BW, Cohen, Y, Loewenthal, R, Trakhtenbrot, L et al. (2009). Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 6: e1000029.
38. Commission Directive 88/302/EEC of 18 November 1987 adapting to technical progress for the ninth time Council Directive 67/548/EEC on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances. OJEU L133/31.
39. Committee for Advanced Therapies and European Medicines Agency. (2014). Guideline on the risk-based approach according to annex I, part IV of Directive 2001/83/EC applied to Advanced Therapy Medicinal Products. EMA/CAT/CPWP/686637/2011.
40. Shay, T, Jojic, V, Zuk, O, Rothamel, K, Puyraimond-Zemmour, D, Feng, T et al.; ImmGen Consortium. (2013). Conservation and divergence in the transcriptional programs of the human and mouse immune systems. Proc Natl Acad Sci USA 110: 2946-2951.
41. Schneemann, M and Schoeden, G (2007). Macrophage biology and immunology: man is not a mouse. J Leukoc Biol 81: 579; discussion 580.
42. Mestas, J and Hughes, CC (2004). Of mice and not men: differences between mouse and human immunology. J Immunol 172: 2731-2738.
43. Smyth, LA, Ratnasothy, K, Moreau, A, Alcock, S, Sagoo, P, Meader, L et al. (2013). Tolerogenic donor-derived dendritic cells risk sensitization in vivo owing to processing and presentation by recipient APCs. J Immunol 190: 4848-4860.
44. International conference of harmonisation of technical requirements for registration of pharmaceuticals for human use. (1997). ICH Harmonised Tripartite Guideline. Preclinical Safety Evaluation of Biotechnology-derived Pharmaceuticals S6(R1). Federal Register 62: 61515.
45. Hume, DA and MacDonald, KP (2012). Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119: 1810-1820.
46. Trzonkowski, P, Bieniaszewska, M, Juscinska, J, Dobyszuk, A, Krzystyniak, A, Marek, N et al. (2009). First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127-T regulatory cells. Clin Immunol 133: 22-26.
47. Giannoukakis, N, Phillips, B, Finegold, D, Harnaha, J and Trucco, M (2011). Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 34: 2026-2032.
48. Tan, J, Wu, W, Xu, X, Liao, L, Zheng, F, Messinger, S et al. (2012). Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 307: 1169-1177.
49. Flory, E and Reinhardt, J (2013). European regulatory tools for advanced therapy medicinal products. Transfus Med Hemother 40: 409-412.
50. Directive 2004/23/EC of the European Parliament and of the Council (2004) on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. OJEU L102/48.
51. Hutchinson, JA, Riquelme, P, Geissler, EK and Fändrich, F (2011). Human regulatory macrophages. Method Mol Biol 677: 181-192.